Department of Cardiovascular Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Department of Cardiovascular Medicine, The First Branch of the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Respir Res. 2020 Apr 15;21(1):83. doi: 10.1186/s12931-020-01352-w.
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. The cardiac injury is a common condition among the hospitalized patients with COVID-19. However, whether N terminal pro B type natriuretic peptide (NT-proBNP) predicted outcome of severe COVID-19 patients was unknown.
The study initially enrolled 102 patients with severe COVID-19 from a continuous sample. After screening out the ineligible cases, 54 patients were analyzed in this study. The primary outcome was in-hospital death defined as the case fatality rate. Research information and following-up data were obtained from their medical records.
The best cut-off value of NT-proBNP for predicting in-hospital death was 88.64 pg/mL with the sensitivity for 100% and the specificity for 66.67%. Patients with high NT-proBNP values (> 88.64 pg/mL) had a significantly increased risk of death during the days of following-up compared with those with low values (≤88.64 pg/mL). After adjustment for potential risk factors, NT-proBNP was independently correlated with in-hospital death.
NT-proBNP might be an independent risk factor for in-hospital death in patients with severe COVID-19.
ClinicalTrials, NCT04292964. Registered 03 March 2020.
由严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）在中国爆发，已被宣布为国际关注的突发公共卫生事件。心脏损伤是住院 COVID-19 患者的常见情况。然而，N 末端脑钠肽前体（NT-proBNP）是否可预测重症 COVID-19 患者的预后尚不清楚。
本研究最初连续纳入了 102 例重症 COVID-19 患者。在排除不合格病例后，本研究分析了 54 例患者。主要结局为住院死亡，定义为病死率。研究信息和随访数据均来自他们的病历。
NT-proBNP 预测住院死亡的最佳截断值为 88.64 pg/mL，其敏感性为 100%，特异性为 66.67%。与低值（≤88.64 pg/mL）相比，高 NT-proBNP 值（>88.64 pg/mL）的患者在随访期间死亡的风险显著增加。在调整了潜在的危险因素后，NT-proBNP 与住院死亡独立相关。
NT-proBNP 可能是重症 COVID-19 患者住院死亡的独立危险因素。
ClinicalTrials，NCT04292964。于 2020 年 3 月 3 日注册。
